Company Dossier · Health Care
Thermo Fisher Scientific
- S&P 500
- S&P 100
- Russell 1000
What Thermo Fisher Scientific is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 27, 2026: $46.3 billion, up 7.2% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 27, 2026: $7.32 billion, up 19% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 27, 2026: $1.70 billion, up 21% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $3.00 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to December 31, 2025: $7.76 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (October 21, 2026): sentiment 0.75 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.82 of 1.Palanor Discourse
- Latest annual report (filed February 26, 2026): 0 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $61.6 million on the open market.SEC Form 4
- 2,632 institutional managers reported a position at June 30, 2026 (+18 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 95 (133 a year earlier).U.S. Department of Labor (OFLC)
Risk events (12 months): 2 — latest OSHA inspection, Jun 30, 2026 →
Company Posture
How Company Posture is measured →What Thermo Fisher Scientific is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Confident
Expanding ↔ Retrenching
Steady
- Capital spending84th pct
- Debt raised74th pct
- Buybacks vs capex22nd pct
- Hiring filings33rd pct
- Deals and private raises49th pct
- Patent publications21st pct
Confident ↔ Hedging
Confident
- Call sentiment86th pct
- Call confidence70th pct
- Guidance changes—
- Risk factors added73rd pct
- Insider open-market trades38th pct
- + Call sentiment
- + Call confidence
- + Risk factors added
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver54th pct
- Stress filings48th pct
Credit
How these are built →Thermo Fisher Scientific's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$42.5B
- Due within a year $3.4B
- Longer term $39.2B
- Default point $23.0B (short + ½ long)
Finance leases included · Jun 27, 2026 filing
Bonds priced, last 12 months
$3.8B
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
| Priced | Amount | Coupon | Matures | Spread | Yield |
|---|---|---|---|---|---|
| Feb 9, 2026 | $750M | 5.546% | 2046 (20y) | +75bp | 5.546% |
| Feb 9, 2026 | $1.3B | 4.902% | 2036 (10y) | +70bp | 4.902% |
| Feb 9, 2026 | $750M | 4.550% | 2033 (7y) | +62bp | 4.586% |
| Feb 9, 2026 | $1B | 4.215% | 2031 (5y) | +47bp | 4.215% |
| Nov 24, 2025 | €1.1B | 3.628% | 2035 (10y) | +93bp | 3.628% |
| Nov 24, 2025 | €1B | EURIBOR + 28bp | 2027 (2y) | — | — |
| Sep 30, 2025 | $500M | 4.894% | 2037 (12y) | +75bp | 4.894% |
| Sep 30, 2025 | $500M | 4.200% | 2031 (5y) | +50bp | 4.227% |
| Sep 30, 2025 | $750M | 4.794% | 2035 (10y) | +65bp | 4.794% |
| Sep 30, 2025 | $750M | 4.473% | 2032 (7y) | +55bp | 4.473% |
| Nov 28, 2023 | $500M | 5.200% | 2034 (10y) | +87bp | 5.218% |
| Nov 28, 2023 | $1B | 5.000% | 2029 (5y) | +72bp | 5.048% |
From the pricing term sheets Thermo Fisher Scientific filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name Thermo Fisher Scientific, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralThermo Fisher Scientific Inc (TMO) Shares Fall 3.3% -- What GF Score of 85 Tells Investors
gurufocus.com · via Marketaux · Oct 1, 2026
- NeutralThermo Fisher Scientific Inc (TMO) Stock Up 0.1% but GF Value Says Overvalued -- GF Score: 85/100
gurufocus.com · via Marketaux · Sep 30, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (MONUMENT ADVOCACY)third_quarter 2026 · $0.1 million
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 19, 2026LobbyingLobbying report (ERNST & YOUNG LLP (WASHINGTON COUNCIL ERNST & YOUNG))third_quarter 2026
- Oct 19, 2026LobbyingLobbying report (GORDON THOMAS HONEYWELL GOVERNMENTAL AFFAIRS)third_quarter 2026 · $0.0 million
- Oct 16, 2026LobbyingLobbying report (BLUEBIRD STRATEGIES)third_quarter 2026 · $0.0 million
- Oct 15, 2026LobbyingLobbying report (THERMO FISHER SCIENTIFIC INC.)third_quarter 2026 · $0.6 million
- Jul 20, 2026LobbyingLobbying report (MONUMENT ADVOCACY)second_quarter 2026 · $0.1 million
- Jul 20, 2026LobbyingLobbying report (ERNST & YOUNG LLP (WASHINGTON COUNCIL ERNST & YOUNG))second_quarter 2026
- Jul 17, 2026LobbyingLobbying report (GORDON THOMAS HONEYWELL GOVERNMENTAL AFFAIRS)second_quarter 2026 · $0.0 million
- Jun 30, 2026Risk event
- May 26, 20268-KShareholder vote resultsItem 5.07
- Feb 26, 202610-KAnnual report (10-K)0 risk factors added, 0 removed
- Feb 12, 20268-KMaterial agreement signedItem 1.01
- Jan 12, 20268-KDirector or officer changeItem 5.02
- Dec 9, 2025Risk event
- Dec 1, 20258-KMaterial agreement signedItem 1.01
- Oct 7, 20258-KMaterial agreement signedItem 1.01
- Sep 4, 2025Risk event
- Jul 23, 20258-KDirector or officer changeItem 5.02
- May 28, 20258-KShareholder vote resultsItem 5.07
- May 22, 20258-KDirector or officer changeItem 5.02
- Feb 20, 202510-KAnnual report (10-K)0 risk factors added, 0 removed
- Feb 19, 20258-KDirector or officer changeItem 5.02
- Feb 22, 202410-KAnnual report (10-K)1 risk factors added, 0 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Danaher Corp. DHR | $25.1B | $5.5B | Jun 26, 2026 |
| Abbott Laboratories ABT | $45.1B | $7.4B | Mar 31, 2026 |
| Molina Healthcare MOH | $44.5B | −$0.6B | Jun 30, 2026 |
| Bristol Myers Squibb BMY | $49.2B | $11.4B | Jun 30, 2026 |
| Amgen AMGN | $38.1B | $10.2B | Jun 30, 2026 |
| Medtronic MDT | $37.5B | $6.1B | Jul 31, 2026 |
| Pfizer Inc. PFE | $63.7B | $11.0B | Jun 28, 2026 |
| AbbVie Inc. ABBV | $64.4B | $18.2B | Jun 30, 2026 |